Earnings History Data for Silence Therapeutics (SLN) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Silence Therapeutics
Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14-11-2024 | PM | SLN | Silence Therapeutics | 485.00 | -0.63 | -0.42 | 0.00 | Silence Therapeutics reports Q3 results [11/14/2024 3:23 PM] |
13.95 | -1.29 (-8.50%) |
15.24 | 0.0 (0.00%) |
8.94 - 27.72 | 148,671 | 130,000 | 3,130 | ||
| 15-08-2024 | PM | SLN | Silence Therapeutics | 497.00 | -0.42 | -0.32 | 0.00 | 16.78 | 0.52 (3.20%) |
0.0 | 0.0 (0.00%) |
5.90 - 27.72 | 709,575 | 310,000 | 0 | |||
|
|
||||||||||||||||||
| 16-05-2024 | PM | SLN | Silence Therapeutics | 633.00 | -0.05 | -0.23 | 0.00 | Silence Therapeutics reports Q1 results [5/16/2024 12:45 PM] |
22.99 | 0.66 (2.96%) |
0.0 | 0.0 (0.00%) |
4.84 - 27.72 | 52,217 | 130,000 | 0 | ||
| 13-03-2024 | PM | SLN | Silence Therapeutics Plc | 891.13 | -0.47 | -0.25 | -0.46 | Silence Therapeutics reports FY results [3/13/2024 7:07 AM] |
25.54 | -0.36 (-1.39%) |
26.80 | 0.90 (3.47%) |
4.55 - 26.83 | 412,870 | 270,000 | 119,497 | ||
| 14-11-2023 | PM | SLN | Silence Therapeutics | 275.00 | -0.28 | -0.56 | 0.00 | Silence Therapeutics GAAP EPS of -7.4p, revenue of £2.8M [11/14/2023 9:05 AM] |
9.24 | 0.23 (2.55%) |
0.0 | 0.0 (0.00%) |
4.55 - 17.99 | 13,252 | 40,000 | 0 | ||
| 16-08-2023 | PM | SLN | Silence Therapeutics | 183.00 | -0.36 | -0.59 | 0.00 | Silence Therapeutics GAAP EPS of -9.60p, revenue of £9.1M [8/16/2023 2:47 PM] |
6.38 | 0.26 (4.25%) |
6.45 | 0.33 (5.39%) |
4.55 - 17.99 | 14,908 | 50,000 | 101 | ||
| 15-03-2023 | PM | 7:00 AM ET (Mar 15) |
SLN | Silence Therapeutics Plc | 1,340 | -0.46 | 0.45 | -0.42 | Silence Therapeutics reports FY results [3/15/2023 7:17 AM] |
9.34 | -0.32 (-3.36%) |
0.0 | 0.0 (0.00%) |
7.80 - 21.32 | 41,598 | 60,000 | 0 | |
| 10-11-2022 | PM | Before the open (Nov 10) |
SLN | Silence Therapeutics | 438.00 | -0.25 | -0.60 | 0.00 | Silence Therapeutics GAAP EPS of -£0.70 misses by £0.51, revenue of £3.3M [11/10/2022 9:27 AM] |
12.75 | 1.00 (8.49%) |
0.0 | 0.0 (0.00%) |
7.80 - 26.84 | 20,199 | 30,000 | 0 | |
| 17-03-2022 | PM | 0:00 AM ET (Mar 17) |
SLN | Silence Therapeutics Plc | 493.82 | -0.42 | -0.62 | 0.00 | Silence Therapeutics GAAP EPS of 44.30p, revenue of £12.41M [3/17/2022 7:16 AM] |
16.70 | -0.30 (-1.76%) |
17.85 | 0.85 (5.00%) |
15.29 - 35.00 | 9,298 | 21,240 | 0 | |